Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status

Tremelimumab, an anti‐cytotoxic T‐lymphocyte antigen‐4 monoclonal antibody that enhances T‐cell activation, was evaluated in a randomized, double‐blind, placebo‐controlled, phase IIb study (NCT01843374) in patients with unresectable malignant mesothelioma. The study demonstrated no clinically meanin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Transl Sci
Autors principals: Baverel, Paul, Roskos, Lorin, Tatipalli, Manasa, Lee, Nancy, Stockman, Paul, Taboada, Maria, Vicini, Paolo, Horgan, Kevin, Narwal, Rajesh
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6742946/
https://ncbi.nlm.nih.gov/pubmed/30883000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12633
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars